1-20 of 75
Yan Zhang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PO4-04-07: Efficacy, safety and translational study of pyrotinib combined with albumin-bound paclitaxel as firstline treatment of HER-2 positive metastatic breast cancer

Huihui Li, Xiaochu Man, Sha Yin, Dongdong Zhou, Baoxuan Zhang, Shu Fang, Fangchao Zheng, Chao Li, Xinzhao Wang, Wei Huang, Linlin Wang, Qingqing He, Hui Fu, Yan Zhang, Changrui Liu, Lin Dong, Xianguang Zhao, Liang Xu, Xiao Sun, Bingjie Fan, Lihua Song, Zhengbo Zhou, Qiaorui Tan, Jinming Yu
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO4-04-07.
https://doi.org/10.1158/1538-7445.SABCS23-PO4-04-07
Published: 02 May 2024
View article titled, Abstract PO4-04-07: Efficacy, safety and translational study of pyrotinib combined with albumin-bound paclitaxel as firstline treatment of HER-2 positive metastatic breast cancer
Journal Articles

Abstract CT119: Safety and efficacy of HS-10370 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)

Xiaorong Dong, Xiangjiao Meng, Yan Zhang, Yan Wang, Jianhua Chen, Liang Han, Qiming Wang, Zhong Lin, Hongying Wei, Siheng Lin, Chuan Li, Qiong Wu
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT119.
https://doi.org/10.1158/1538-7445.AM2024-CT119
Published: 05 April 2024
View article titled, Abstract CT119: Safety and efficacy of HS-10370 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)
Journal Articles

Abstract 4997: Auranofin enhances the efficacy of anti-PD1 immunotherapy

Zichen Zhao, Shichuan Hu, Yan Zhang
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4997.
https://doi.org/10.1158/1538-7445.AM2024-4997
Published: 22 March 2024
View article titled, Abstract 4997: Auranofin enhances the efficacy of anti-PD1 immunotherapy
Journal Articles

Abstract 4533: Identification of DAT-2000A, a novel potent PARG inhibitor that selectively inhibits PARPi-resistant and homologous-recombination-deficient tumors

Dan Yan, Yan Zhang, Zhangqi Yu, Yao Zhang, Jingxi Zhang, Bin Wang, Huixian Chen, Jingxue Shi, Zhiwei Bao, Xiaoling Lin, Jincong Zhuo, Kevin Zhou
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4533.
https://doi.org/10.1158/1538-7445.AM2024-4533
Published: 22 March 2024
View article titled, Abstract 4533: Identification of DAT-2000A, a novel potent PARG inhibitor that selectively inhibits PARPi-resistant and homologous-recombination-deficient tumors
Journal Articles

Abstract 4532: Discovery of DAT-1000A, a potent Polθ inhibitor that significantly enhances anti-tumor efficacy in combination with PARP inhibitor in homologous-recombination-deficient tumors

Dan Yan, Yao Zhang, Yan Zhang, Jingxi Zhang, Bin Wang, Huixian Chen, Jingxue Shi, Xiaoling Lin, Jincong Zhuo, Kevin Zhou
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4532.
https://doi.org/10.1158/1538-7445.AM2024-4532
Published: 22 March 2024
View article titled, Abstract 4532: Discovery of DAT-1000A, a potent Polθ inhibitor that significantly enhances anti-tumor efficacy in combination with PARP inhibitor in homologous-recombination-deficient tumors
Journal Articles

Abstract 5135: Tertiary lymphoid structures and T-cell aggregates signal a robust anti-tumor immune response in a subset of leiomyosarcoma patients

Aditya Suru, Alexandre Maalouf, Lingling Chen, Ada Tam, William Villasi, Kaushal Sharma, Lindy Zhang, Christian Meyer, Jonathan Greer, Fabian Johnston, Carol Morris, Sophia Strike, Adam Levin, Daniel Rhee, Brian Ladle, Kornel Schuebel, Yan Zhang, Rulin Wang, Srinivasan Yegnasubramanian, John Gross, Robert Anders, Andrew Pardoll, Nicolas Llosa
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5135.
https://doi.org/10.1158/1538-7445.AM2024-5135
Published: 22 March 2024
View article titled, Abstract 5135: Tertiary lymphoid structures and T-cell aggregates signal a robust anti-tumor immune response in a subset of leiomyosarcoma patients
Journal Articles

Abstract 7243: CRISPR-cas9 genetic targeting of metastatic pancreatic cancer

Kirsten Bowland, Jiaying Lai, Selina Shiqing K. Teh, Alexis Bennett, Alyza Skaist, Yan Zhang, Elizabeth Thompson, Ralph H. Hruban, Nicholas J. Roberts, Rachel Karchin, Christine A. Iacobuzio-Donahue, James R. Eshleman
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 7243.
https://doi.org/10.1158/1538-7445.AM2024-7243
Published: 22 March 2024
View article titled, Abstract 7243: CRISPR-cas9 genetic targeting of metastatic pancreatic cancer
Journal Articles

Abstract CT219: Efficacy and safety of Low dose radiotherapy (LDRT) concurrent Atezolizumab (Atezo) plus chemotherapy as first line (1L) therapy for ES-SCLC: Primary analysis of Phase II MATCH study

Lin Zhou, Jianguo Sun, Conghua Xie, Youling Gong, Meijuan Huang, Zhiyong Yuan, Lin Wu, Hui Wang, Nan Bi, Yaping Xu, Jiang Zhu, Yongmei Liu, Yan Zhang, Min Fan, Bingwen Zou, Min Yu, Yanying Li, Feifei Na, Weigang Xiu, Yong Xu, Jin Wang, Xuanwei Zhang, Jianxin Xue, You Lu
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT219.
https://doi.org/10.1158/1538-7445.AM2023-CT219
Published: 14 April 2023
View article titled, Abstract CT219: Efficacy and safety of Low dose radiotherapy (LDRT) concurrent Atezolizumab (Atezo) plus chemotherapy as first line (1L) therapy for ES-SCLC: Primary analysis of Phase II MATCH study
Journal Articles

Abstract 3400: TY-2136b, a next generation ROS1/TRK/ALK inhibitor, potently inhibits kinase and cell proliferation activities of tumor cells bearing drug-dependent acquired mutations

Chengshan Niu, Apeng Liang, Yuge Dou, Kaige Ji, Meihua Li, Yanchao Zhao, Yan Zhang, Zhongwei Guo, Aishen Gong, Mingyu Jiang, Shaoqing Chen, Xiugui Chen, Jun Li, Yusheng Wu
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3400.
https://doi.org/10.1158/1538-7445.AM2023-3400
Published: 04 April 2023
View article titled, Abstract 3400: TY-2136b, a next generation ROS1/TRK/ALK inhibitor, potently inhibits kinase and cell proliferation activities of tumor cells bearing drug-dependent acquired mutations
Journal Articles

Abstract 2260: Characterizing tumor stromal evolution after neoadjuvant anti-PD-1 therapy in Merkel cell carcinoma

Joel C. Sunshine, Tracee L. McMiller, Alyza Skaist, Yan Zhang, Alan Berger, Kornel Schuebel, Jennifer Meyers, Julie S. Deutsch, Aleksandra Ogurtsova, Elizabeth L. Engle, Leslie Cope, Janis M. Taube, Suzanne L. Topalian
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 2260.
https://doi.org/10.1158/1538-7445.AM2023-2260
Published: 04 April 2023
View article titled, Abstract 2260: Characterizing tumor stromal evolution after neoadjuvant anti-PD-1 therapy in Merkel cell carcinoma
Journal Articles

Abstract 5979: TY-0540, a highly potent CDK2/4/6 inhibitor, attenuates acquired resistance against CDK4/6 inhibition

Meihua Li, Chengshan Niu, Mingtao Chen, Kaige Ji, Hui Xu, Shengli Dong, Yan Zhang, Qinguo Meng, Yuge Dou, Yijun Wang, Rui Wu, Yian Tu, Chao Zhou, Apeng Liang, Huan Wang, Rongzhen Ni, Aishen Gong, Hui Su, Mingyu Jiang, Feng Xing, Shaoqing Chen, Xiugui Chen, Jun Li, Yusheng Wu
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5979.
https://doi.org/10.1158/1538-7445.AM2023-5979
Published: 04 April 2023
View article titled, Abstract 5979: TY-0540, a highly potent CDK2/4/6 inhibitor, attenuates acquired resistance against CDK4/6 inhibition
Journal Articles

Abstract 1724: SCR-8388, a potent and selective SOS1::KRAS inhibitor, is effective in KRAS-addicted cancers

Feng Zhou, Guimei Yang, Feng Tang Tang, Yan Zhang, Shengwei Yang, Wenqing Yang, Liting Xue, Ping Chen, Renhong Tang
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1724.
https://doi.org/10.1158/1538-7445.AM2023-1724
Published: 04 April 2023
View article titled, Abstract 1724: SCR-8388, a potent and selective SOS1::KRAS inhibitor, is effective in KRAS-addicted cancers
Journal Articles

Abstract 6264: NUV-868, a novel BD2-selective BET inhibitor, in combination with enzalutamide or olaparib, inhibits growth of solid tumor xenografts

Hitisha Patel, Jennifer Hertzog, Laura Heller, Spandana Vootukuri, Yan Zhang, Chris Miller, Gary Hattersley
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 6264.
https://doi.org/10.1158/1538-7445.AM2023-6264
Published: 04 April 2023
View article titled, Abstract 6264: NUV-868, a novel BD2-selective BET inhibitor, in combination with enzalutamide or olaparib, inhibits growth of solid tumor xenografts
Journal Articles

Abstract 2819: Genome-wide CRISPR screen identifies NANP as a radio-sensitizing target of GBM by regulating NF-κB pathway

Yingwen Ding, Ze-Yan Zhang, Ravesanker Ezhilarasan, Aram S. Modrek, Jerome Karp, Erik P. Sulman
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 2819.
https://doi.org/10.1158/1538-7445.AM2023-2819
Published: 04 April 2023
View article titled, Abstract 2819: Genome-wide CRISPR screen identifies NANP as a radio-sensitizing target of GBM by regulating NF-κB pathway
Journal Articles

Abstract 671: Cryo-electronmicroscopy of PI3K reveals additional regulatory features

Jonathan R. Hart, Su Yang, Xiao Liu, Yingna Xu, Xinyu Zou, Huibing Zhang, Qingtong Zhou, Tian Xia, Yan Zhang, Dehua Yang, Ming-Wei Wang, Peter K. Vogt
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 671.
https://doi.org/10.1158/1538-7445.AM2022-671
Published: 15 June 2022
View article titled, Abstract 671: Cryo-electronmicroscopy of PI3K reveals additional regulatory features
Journal Articles

Abstract 1862: Naphthoquinone analogues inhibit Wnt/β-catenin signaling and colorectal cancer tumorigenesis

Rosalie G. Hoyle, Andrew Morris, Piyusha Pagare, Shadid Uz Zaman, Zhikun Ma, Yan Zhang, Jiong Li
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1862.
https://doi.org/10.1158/1538-7445.AM2022-1862
Published: 15 June 2022
View article titled, Abstract 1862: Naphthoquinone analogues inhibit Wnt/β-catenin signaling and colorectal cancer tumorigenesis
Journal Articles

Abstract 5642: Discovery of SCR-8079, a novel and selective CDK2/4/6 inhibitor overcomes the resistance to CDK4/6 inhibition and demonstrates broad anti-tumor activities in breast cancers

Feng Zhou, Guimei Yang, Feng Tang, Yan Zhang, Wenqing Yang, Liting Xue, Ping Chen, Renhong Tang
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5642.
https://doi.org/10.1158/1538-7445.AM2022-5642
Published: 15 June 2022
View article titled, Abstract 5642: Discovery of SCR-8079, a novel and selective CDK2/4/6 inhibitor overcomes the resistance to CDK4/6 inhibition and demonstrates broad anti-tumor activities in breast cancers
Journal Articles

Abstract CT170: D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156)

Shun Lu, Yiping Zhang, Guojun Zhang, Jianying Zhou, Shundong Cang, Ying Cheng, Gang Wu, Peiguo Cao, Dongqing Lv, Xiangming Jin, Hong Jian, Chengshui Chen, Guanming Jiang, Panwen Tian, Kai Wang, Hui Zhao, Gongyan Chen, Qun Chen, Cuimin Ding, Junquan Yang, Renhua Guo, Guoping Sun, Bin Wang, Liyan Jiang, Wu Zhuang, Zhe Liu, Jian Fang, Yunpeng Liu, Jian Zhang, Jun Chen, Yueyin Pan, Qitao Yu, Min Zhao, Jiuwei Cui, Dianming Li, Tienan Yi, Zhuang Yu, Yan Yang, Yan Zhang, Xiuyi Zhi, Yunchao Huang, Rong Wu, Liangan Chen, Aimin Zang, Lejie Cao, Qingshan Li, Xiaoling Li, Yong Song, Donglin Wang, Shucai Zhang
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT170.
https://doi.org/10.1158/1538-7445.AM2021-CT170
Published: 01 July 2021
View article titled, Abstract CT170: D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156)
Journal Articles

Abstract 1338: Discovery of novel, potent USP7 inhibitors that upregulate p53 leading to anti-proliferative effects in cancer cells

Alan Futran, Tao Lu, Katherine Amberg-Johnson, Xiaoxiao Yang, Saidi He, Jeffrey Bell, Sarah Boyce, Markus Dahlgren, Karen Dingley, Liping Fang, Heidi Koldsoe, Zef Konst, Fang-Yu Lin, Robert Pelleltier, Heng Qian, Mats Svensson, Michael Trzoss, Jie Xu, Shuping Xu, Zhaowu Xu, Engin Yapici, Yan Zhang, Li Xing, Takao Suzuki, Xianhai Huang, Jiayi Xu, Hamish Wright, Kristian Jensen, Wayne Tang, Tao Guo, Karen Akinsanya, David Madge
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1338.
https://doi.org/10.1158/1538-7445.AM2021-1338
Published: 01 July 2021
View article titled, Abstract 1338: Discovery of novel, potent USP7 inhibitors that upregulate p53 leading to anti-proliferative effects in cancer cells
Journal Articles

Abstract 3004: Establishment of KRAS G12C mutant patient-derived xenograft (PDX) models for pre-clinical evaluation of KRAS G12C targeted anticancer therapy

Wenting Shi, Xuzhen Tang, Jingying Zhang, Xinhong Kuang, Yan Zhang, Jingjing Wang, Qingyang Gu, Qunsheng Ji
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 3004.
https://doi.org/10.1158/1538-7445.AM2021-3004
Published: 01 July 2021
View article titled, Abstract 3004: Establishment of KRAS G12C mutant patient-derived xenograft (PDX) models for pre-clinical evaluation of KRAS G12C targeted anticancer therapy